S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among ethiopians

被引:78
|
作者
Persson, I
Aklillu, E
Rodrigues, F
Bertilsson, L
IngelmanSundberg, M
机构
[1] KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,S-17177 STOCKHOLM,SWEDEN
[2] UNIV ADDIS ABABA,FAC MED,ADDIS ABABA,ETHIOPIA
[3] HUDDINGE UNIV HOSP,KAROLINSKA INST,DIV CLIN PHARMACOL,DEPT MED LAB SCI & TECHNOL,S-14186 HUDDINGE,SWEDEN
来源
PHARMACOGENETICS | 1996年 / 6卷 / 06期
关键词
cytochrome P450; mephenytoin; omeprazole; proguanil; genotype; genetic polymorphism;
D O I
10.1097/00008571-199612000-00005
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The polymorphic metabolism of S-mephenytoin and the distribution of two known deleterious mutant CYP2C19 alleles was determined among 114 healthy unrelated black Ethiopians, Six subjects (5.2%) were poor metabolizers (PMs) of S-mephenytoin, The frequencies of the defective CYP2C19*2 (CYP2C19m1) and CYP2C19+3 (CYP2C19m2) alleles were 0.14 and 0.02, respectively, Three of the PMs were homozygous for the CYP2C19*2 allele and the remaining three PMs were heterozygous for both the CYP2C192 and CYP2C19*3 mutant alleles, It is concluded that the frequency of PMs for S-mephenytoin is similar in Ethiopians, Zimbabweans and Caucasians and that the CYP2C19*3 allele, for the first time identified in a black population, together with the CYP2C19*2 allele account for all of the defective CYP2C19 alleles among the Ethiopan PMs.
引用
收藏
页码:521 / 526
页数:6
相关论文
共 50 条
  • [1] CYP2C19 genotype and S-mephenytoin 4′-hydroxylation phenotype in a Chinese Dai population
    Nan He
    Feng-Xiang Yan
    Song-Lin Huang
    Wei Wang
    Zhou-Sheng Xiao
    Zhao-Qian Liu
    Hong-Hao Zhou
    European Journal of Clinical Pharmacology, 2002, 58 : 15 - 18
  • [2] CYP2C19 genotype and S-mephenytoin 4′-hydroxylation phenotype in a Chinese Dai population
    He, N
    Yan, FX
    Huang, SL
    Wang, W
    Xiao, ZS
    Liu, ZQ
    Zhou, HH
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 58 (01) : 15 - 18
  • [3] Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype
    Chang, M
    Dahl, ML
    Tybring, G
    Gotharson, E
    Bertilsson, L
    PHARMACOGENETICS, 1995, 5 (06): : 358 - 363
  • [4] A MULTIFAMILY STUDY ON THE RELATIONSHIP BETWEEN CYP2C19 GENOTYPE AND S-MEPHENYTOIN OXIDATION PHENOTYPE
    BROSEN, K
    DEMORAIS, SMF
    MEYER, UA
    GOLDSTEIN, JA
    PHARMACOGENETICS, 1995, 5 (05): : 312 - 317
  • [5] CYP2C19 genotype determines enzyme activity and inducibility of S-mephenytoin hydroxylase
    Zhou, HH
    CLINICA CHIMICA ACTA, 2001, 313 (1-2) : 203 - 208
  • [6] ALTERATIONS IN HUMAN CYP2C19, THE MAJOR S-MEPHENYTOIN 4'-HYDROXYLASE, IN POOR METABOLIZERS OF S-MEPHENYTOIN
    GOLDSTEIN, JA
    GHANAYEM, BI
    FALETTO, M
    LASKER, J
    SULLIVAN, T
    ROMKESSPARKS, M
    RAUCY, J
    WILKINSON, G
    MEYER, U
    DEMORAIS, SMF
    FASEB JOURNAL, 1994, 8 (07): : A1257 - A1257
  • [7] Identification of human CYP2C19 residues that confer S-mephenytoin 4′-hydroxylation activity to CYP2C9
    Tsao, CC
    Wester, MR
    Ghanayem, B
    Coulter, SJ
    Chanas, B
    Johnson, EF
    Goldstein, JA
    BIOCHEMISTRY, 2001, 40 (07) : 1937 - 1944
  • [8] Lack of effect of chloroquine on the debrisoquine (CYP2D6) and S-mephenytoin (CYP2C19) hydroxylation phenotypes
    Masimirembwa, CM
    Gustafsson, LL
    Dahl, ML
    Abdi, YA
    Hasler, JA
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 41 (04) : 344 - 346
  • [9] THE ROLE OF S-MEPHENYTOIN HYDROXYLASE (CYP2C19) IN THE METABOLISM OF THE ANTIMALARIAL BIGUANIDES
    WRIGHT, JD
    HELSBY, NA
    WARD, SA
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 39 (04) : 441 - 444
  • [10] Evaluation of the Effects of 20 Nonsynonymous Single Nucleotide Polymorphisms of CYP2C19 on S-Mephenytoin 4′-Hydroxylation and Omeprazole 5′-Hydroxylation
    Wang, Huijuan
    An, Nianzhen
    Wang, Hao
    Gao, Yiwen
    Liu, Duan
    Bian, Ting
    Zhu, Juanli
    Chen, Chao
    DRUG METABOLISM AND DISPOSITION, 2011, 39 (05) : 830 - 837